Dr. Reddy's Laboratories Ltd. Announces The Completion Of Fondaparinux Intellectual Property Purchase

HYDERABAD, India--(BUSINESS WIRE)--Dr. Reddy's Laboratories (BSE: 500124) (NSE: DRREDDY) (NYSE: RDY) today announced that it has completed the purchase of worldwide exclusive intellectual property rights for Fondaparinux sodium, its generic anti-coagulant drug, from its Australian partner, Alchemia Limited. Earlier, the company had signed a term sheet for this transaction in September, 2015.

Help employers find you! Check out all the jobs and post your resume.